ALECTOR INC. - COMMON STOCK

Alector to Participate in Upcoming Healthcare Conferences

28 Aug 2025 05:00:00 By Nasdaq GlobeNewswire

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

07 Aug 2025 13:05:02 By Nasdaq GlobeNewswire

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

31 Jul 2025 13:05:00 By Nasdaq GlobeNewswire

Alector Provides Executive Leadership Update

13 Jun 2025 13:05:00 By Nasdaq GlobeNewswire

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

03 Jun 2025 05:00:00 By Nasdaq GlobeNewswire

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

08 May 2025 13:05:03 By Nasdaq GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences

06 May 2025 05:00:02 By Nasdaq GlobeNewswire

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

17 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Alector Provides Executive Leadership Update

28 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

26 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences

25 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

19 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

13 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update

25 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

14 Nov 2024 13:05:46 By Nasdaq GlobeNewswire

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

06 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

19 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences

29 Aug 2024 04:00:00 By Nasdaq GlobeNewswire

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

07 Aug 2024 13:05:00 By Nasdaq GlobeNewswire

Alector to Host Mid-Year Earnings Conference Call

31 Jul 2024 13:05:00 By Nasdaq GlobeNewswire